Harmony Biosciences Holdings, Inc.
3.15xPrice / tangible book
Market cap
$2.46B
Tangible equity
$780.80M
Price / tangible book
3.15x
Price / book
2.83x
Return on equity
18.2%
Return on assets
12.5%
Efficiency ratio
—
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HRMY stock price at premium vs SYF $42.25 current versus $23.34 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SYF's multiple
Implied fair value · at HRMY's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Multiple premium
Multiple premium
Profitability lag
Asset efficiency edge
Lower is better
Statements
Bank-focused income statement and equity metrics aligned to the reporting windows.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · SYF FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / tangible book
Market cap
$2.46B
Tangible equity
$780.80M
Price / tangible book
3.15x
Price / book
2.83x
Return on equity
18.2%
Return on assets
12.5%
Efficiency ratio
—
Price / tangible book
Market cap
$26.00B
Tangible equity
$14.15B
Price / tangible book
1.84x
Price / book
1.55x
Return on equity
21.2%
Return on assets
3.0%
Efficiency ratio
987.5%
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Synchrony Financial · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.19x
0.91x
Net debt / EBITDA
Leverage against operating earnings
-2.41x
0.02x
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
$14.97B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
CAPITAL ONE FINANCIAL CORP
HRMY vs COF
American Express Company
HRMY vs AXP
JPMorgan Chase & Co.
HRMY vs JPM
Citigroup Inc.
HRMY vs C
$163.66M
$15.18B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.